However, in this study, we found that the genetic alterations of CEMIP appeared in multiple cancers, including invasive BC, suggesting that mutations (that is, missense and truncating) of CEMIP may be responsible for the formation and progression of aggressive BC, especially truncating in the G380Afs*28 of mucin2 domain of CEMIP. Although studies found that CEMIP mutation happens in invasive BC cell lines, like MDA-MB-435 and MDA-MB-231 (Zhang et al., 2014), the mechanism of this needs more experiments to explore. Here, CEMIP is linked to breast cancer.